KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsCash from RestructuringChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Resmed (RMD) Other financing activities (2016 - 2021)

Resmed (RMD) has disclosed Other financing activities for 13 consecutive years, with $16.1 million as the latest value for Q4 2021.

  • For the quarter ending Q4 2021, Other financing activities rose 4.76% year-over-year to $16.1 million, compared with a TTM value of $29.7 million through Dec 2021, down 33.4%, and an annual FY2021 reading of -$50.2 million, down 9.01% over the prior year.
  • Other financing activities was $16.1 million for Q4 2021 at Resmed, down from $17.3 million in the prior quarter.
  • Across five years, Other financing activities topped out at $17.3 million in Q3 2021 and bottomed at -$3.4 million in Q1 2021.
  • Average Other financing activities over 5 years is $10.4 million, with a median of $12.5 million recorded in 2018.
  • The sharpest move saw Other financing activities plummeted 326.34% in 2020, then soared 71.62% in 2021.
  • Year by year, Other financing activities stood at $12.0 million in 2017, then grew by 4.53% to $12.5 million in 2018, then grew by 12.09% to $14.1 million in 2019, then increased by 9.34% to $15.4 million in 2020, then increased by 4.76% to $16.1 million in 2021.
  • Business Quant data shows Other financing activities for RMD at $16.1 million in Q4 2021, $17.3 million in Q3 2021, and -$271000.0 in Q2 2021.